

Fabio Ius

General Information

Name	Ius, Fabio, Prof. Dr. med.
Date of Birth	11.04.1980
Sex	Male
Affiliation	Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School (MHH), Carl-Neuberg-Straße 1, D-30625 Hannover, Germany Phone: +49-(0)1761-5328012 E-Mail: ius.fabio@mh-hannover.de; ius.r@libero.it
Current Position	Consultant (Oberarzt), Director of the Lung and Heart Transplantation Programs, Department of Cardiothoracic, Transplant and Vascular Surgery (HTTG), Hannover Medical School (MHH)

Academic Education

Since 2020	Principal investigator, German Center for Lung Research (DZL), Hannover, Germany.
Since 2020	Staff Surgeon (Oberarzt) of HTTG, MHH.
Since 2020	Director of the Lung and Heart-Lung Transplantation Program, MHH.
2022 – 2023	Coordinator, Disease Area Regeneration and Organ Replacement, German Center for Lung Research, Hannover, Germany.
2019 - 2023	Director of the Heart Transplantation Program, MHH.
2017 - 2019	Junior Consultant, Department of Cardiothoracic, Transplant and Vascular Surgery (Prof. A. Haverich), Hannover Medical School, Germany.
2011 - 2017	Resident, Department of Cardiothoracic, Transplant and Vascular Surgery (Prof. A. Haverich), Hannover Medical School, Germany.
2006 - 2011	Resident, Department of Cardiothoracic surgery (Prof. U. Livi), University Hospital, Udine, Italy.
1999 - 2005	Faculty of Medicine and Surgery, University Hospital, Udine, Italy. Thesis: <i>“Metabolic and cardiovascular responses to exercise testing in asymptomatic patients with mild-moderate degenerative aortic stenosis”</i> Result: 110/110 cum laude.

Scientific Degrees

2024	Außerplanmäßige Professur, Hannover Medical School, Germany.
2022	Habilitation, Venia Legendi in Cardiac Surgery, Hannover Medical School.
2016	Promotion, Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery. Thesis: <i>“Early donor-specific antibodies in lung transplantation: risk factors and impact on survival”</i> . Supervisor: Prof. Dr. Warnecke. Result: magna cum laude.
2015	Lean Six Sigma Green Belt.

Academic and Research Positions

Clinical research fields: lung transplantation, heart transplantation, ECMO, aortic valve surgery, mitral valve surgery, CTEPH.

Additional Information

Awards:

- 2009 Francis Fontan Award, issued by the “European Association for Cardio-Thoracic Surgery (EACTS).
- 2010 4. Young Investigator Award of the German Transplantation Society (DTG).
- 2019 Career Prize “Grifone d’ Argento” 2019, issued by the University of Udine, Italy.

Memberships:

- Member of the *European Association for Cardio-Thoracic Surgery (EACTS)*.
- Member of the *International Society for Heart and Lung Transplantation (ISHLT)*.
- Member of the *German Transplantation Society (DTG)*.
- Reviewer for the *European Journal of Cardiothoracic Surgery (EJCTS)*, *Transplantation*, *Clinical Transplantation*, *American Journal of Transplantation*, *Journal of Thoracic Disease*.

Publications

 peer-reviewed publications

1. Rega F, Lebreton G, Para M, Michel S, Schramm R, Begot E, Vandendriessche K, Kamla C, Gerosa G, Berman M, Boeken U, Clark S, Ranasinghe A, **Ius F**, Forteza A, Pivodic A, Hennig F, Guenther S, Zuckermann A, Knosalla C, Dellgren G, Wallinder A; NIHP2019 investigators. Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. *Lancet*. 2024 Aug 17; 404(10453):670-682.
2. Heise EL, Chichelnitskiy E, Greer M, Franz M, Aburahma K, Iablonskii P, de Manna ND, Christoph S, Verboom M, Hallensleben M, Boethig D, Avsar M, Welte T, Schwerk N, Sommer W, Haverich A, Warnecke G, Kuehn C, Falk C, Salman J, **Ius F**. Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience. *Am J Transplant*. 2023 Nov;23(11):1740-1756.
3. Iablonskii P, Carlens J, Mueller C, Aburahma K, Niehaus A, Boethig D, Franz M, Floethmann K, Sommer W, Optenhoefel J, Tudorache I, Greer M, Koeditz H, Jack T, Hansmann G, Kuehn C, Horke A, Hansen G, Haverich A, Warnecke G, Avsar M, Salman J, Bobylev D, **Ius F***, Schwerk N*. Indications and outcomes after lung transplantation in children under 12 years of age: a 16-year single center experience. *J Heart Lung Transplant* 2022; 41(2):226-236 (*contributed equally).
4. **Ius F**, Aburahma K, Boethig D, Salman J, Sommer W, Draeger H, Poyanmehr R, Avsar M, Siemeni T, Bobylev D, Optenhoefel J, Wiesner O, Greer M, Schwerk N, Hoepfer MM, Welte T, Haverich A, Kuehn C, Warnecke G, Gottlieb J, Tudorache I. Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation. *J Heart Lung Transplant* 2020; 39(9):915-925.
5. **Ius F**, Müller C, Sommer W, Verboom M, Hallensleben M, Salman J, Siemeni T, Kühn C, Avsar M, Bobylev D, Poyanmehr R, Erdfelder C, Böthig D, Carlens J, Bayir L, Hansen G, Blasczyk R, Falk C, Tecklenburg A, Haverich A, Tudorache I, Schwerk N, Warnecke G. Six-year experience with treatment of early donor-specific anti-HLA antibodies in pediatric lung transplantation using a human immunoglobulin-based protocol. *Pediatr Pulmonol* 2020; 55(3):754-764.
6. **Ius F**, Salman J, Knoefel AK, Sommer W, Nakagiri T, Verboom M, Siemeni T, Poyanmehr R, Bobylev D, Kuehn C, Avsar M, Erdfelder C, Hallensleben M, Boethig D, Hecker H, Schwerk N, Mueller C, Welte T, Falk C, Preissler G, Haverich A, Tudorache I, Warnecke G. Increased frequency of CD4⁺CD25^{high}CD127^{low} T cells early after lung transplant is associated with improved graft survival – a retrospective study. *Transpl Int* 2020; 33(5):503-516.
7. **Ius F**, Verboom M, Sommer W, Poyanmehr R, Knoefel AK, Salman J, Kuehn C, Avsar M, Siemeni T, Erdfelder C, Hallensleben M, Boethig D, Schwerk N, Mueller C, Welte T, Falk C, Haverich A, Tudorache I, Warnecke G. Preemptive treatment of early donor specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation. *Am J Transplant* 2018; 18(9):2295-2304.
8. **Ius F**, Sommer W, Kieneke D, Tudorache I, Kühn C, Avsar M, Siemeni T, Salman J, Erdfelder C, Verboom M, Kielstein J, Tecklenburg A, Greer M, Hallensleben M, Blasczyk R, Schwerk N, Gottlieb J, Welte T, Haverich A, Warnecke G. IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation. *Transplantation* 2016; 100(12):2682-2692.
9. **Ius F**, Sommer W, Tudorache I, Kühn C, Avsar M, Siemeni T, Salman J, Hallensleben M, Kieneke D, Greer M, Gottlieb J, Kielstein JT, Boethig D, Welte T, Haverich A, Warnecke G. Pre-emptive treatment with therapeutic plasma exchange and Rituximab for early donor specific antibodies after lung transplantation. *J Heart Lung Transplant* 2015; 34(1):50-8.
10. **Ius F**, Sommer W, Tudorache I, Kühn C, Avsar M, Siemeni T, Salman J, Hallensleben M, Kieneke D, Greer M, Gottlieb J, Haverich A, Warnecke G. Early donor-specific antibodies in lung transplantation: risk factors and impact on survival. *J Heart Lung Transplant* 2014; 33(12):1255-63.